Dopamine Receptor Neurons

Dopamine Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Dopamine Receptor Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Regions</td>
</tr>
<tr>
<td class="label">D1</td>
<td>Cortex, Striatum, Substantia Nigra pars compacta</td>
</tr>
<tr>
<td class="label">D2</td>
<td>Striatum, VTA, cortex</td>
</tr>
<tr>
<td class="label">D3</td>
<td>Limbic system, nucleus accumbens</td>
</tr>
<tr>
<td class="label">D4</td>
<td>Cortex, hippocampus</td>
</tr>
<tr>
<td class="label">D5</td>
<td>Hippocampus, cortex</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">DARPP-32</td>
<td>PKA substrate</td>
</tr>
<tr>
<td class="label">AKT</td>
<td>PP2A interaction</td>
</tr>
<tr>
<td class="label">GSK3β</td>
<td>Beta-arrestin complex</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>D2 signaling</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Target</td>
</tr>
<tr>
<td class="label">L-DOPA</td>
<td>D1, D2</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>D2/D3</td>
</tr>
<tr>
<td class="label">

Dopamine Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Dopamine Receptor Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Regions</td>
</tr>
<tr>
<td class="label">D1</td>
<td>Cortex, Striatum, Substantia Nigra pars compacta</td>
</tr>
<tr>
<td class="label">D2</td>
<td>Striatum, VTA, cortex</td>
</tr>
<tr>
<td class="label">D3</td>
<td>Limbic system, nucleus accumbens</td>
</tr>
<tr>
<td class="label">D4</td>
<td>Cortex, hippocampus</td>
</tr>
<tr>
<td class="label">D5</td>
<td>Hippocampus, cortex</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">DARPP-32</td>
<td>PKA substrate</td>
</tr>
<tr>
<td class="label">AKT</td>
<td>PP2A interaction</td>
</tr>
<tr>
<td class="label">GSK3β</td>
<td>Beta-arrestin complex</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>D2 signaling</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Target</td>
</tr>
<tr>
<td class="label">L-DOPA</td>
<td>D1, D2</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>D2/D3</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>D2</td>
</tr>
<tr>
<td class="label">Bromocriptine</td>
<td>D2</td>
</tr>
<tr>
<td class="label">Haloperidol</td>
<td>D2</td>
</tr>
<tr>
<td class="label">Risperidone</td>
<td>D2, 5-HT2</td>
</tr>
</table>

Dopamine Receptor Neurons are neurons that express dopamine receptors and respond to dopaminergic signaling. These neurons are critical components of the basal ganglia circuitry, mediating motor control, reward processing, cognition, and motivation. Dysfunction of dopamine receptor signaling is implicated in several neurodegenerative and neuropsychiatric disorders, including Parkinson's Disease, Schizophrenia, and Huntington's Disease.[@beaulieu2019]

Overview

Dopamine receptors are G protein-coupled receptors (GPCRs) classified into two families based on their pharmacological properties and signaling mechanisms:[@missale2018]

• D1-like receptors (D1, D5): Coupled to Gs/olf proteins, stimulate adenylate cyclase and increase cAMP
• D2-like receptors (D2, D3, D4): Coupled to Gi/o proteins, inhibit adenylate cyclase and decrease cAMP

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Neuroanatomy

Brain Region Distribution

Cellular Localization

D1 receptors are predominantly expressed on direct pathway medium spiny neurons (dMSNs) in the striatum, while D2 receptors are expressed on indirect pathway medium spiny neurons (iMSNs).[@kreitzer2008] This segregation forms the basis of the direct and indirect motor pathways.

Molecular Mechanisms

Signaling Pathways

D1-like Receptor Signaling:

• Activation of Gs/olf → activation of adenylate cyclase → increased cAMP → activation of PKA
• PKA phosphorylates DARPP-32, creating a molecular switch that modulates multiple downstream targets
• Regulates ion channel function (e.g., GluR1 AMPA receptor phosphorylation)

• Activation of Gi/o → inhibition of adenylate cyclase → decreased cAMP
• Modulates ion channel function (activates inward-rectifier K+ channels)
• Beta-arrestin recruitment and signaling

Key Protein Interactions

Disease Relevance

Parkinson's Disease

Dopamine receptor neurons are central to Parkinson's disease pathophysiology:[@surmeier2017]

• Loss of dopaminergic neurons in Substantia Nigra pars compacta leads to depleted dopamine in the striatum
• D1 receptors become supersensitive due to denervation
• D2 receptors show reduced signaling efficiency
• L-DOPA therapy initially effective but leads to dyskinesias with chronic use
• D1 and D2 agonists (e.g., pramipexole, ropinirole) used for motor symptoms
• D3 receptors in the ventral striatum may modulate motivation and apathy in PD

Huntington's Disease

• D1 and D2 receptor expression is altered in the striatum
• D1-expressing medium spiny neurons are particularly vulnerable
• Dopamine modulation affects chorea symptoms

Schizophrenia

• D2 receptor hyperactivity is a primary target for antipsychotic drugs
• D1 receptors in prefrontal cortex modulate working memory
• D4 receptor polymorphisms associated with disease susceptibility

Addiction

• D2 receptor density in striatum correlates with reward sensitivity
• Chronic cocaine decreases D2 receptor availability
• D3 receptors implicated in craving and relapse

ADHD

• D4 receptor polymorphisms linked to attention deficits
• D5 receptor variants affect executive function

Therapeutic Implications

Current Therapeutics

Emerging Therapies

• Allosteric modulators for biased signaling
• D1 agonists with improved pharmacokinetics
• D3-selective compounds for neuropsychiatric indications
• mGluR5-negative allosteric modulators for modulating dopaminergic tone

Research Methods

Experimental Approaches

• Radioligand binding (e.g., [^11C]raclopride for PET)
• Immunohistochemistry for receptor localization
• In situ hybridization for mRNA expression
• CRISPR-Cas9 for genetic manipulation
• Optogenetics for circuit-specific manipulation

Animal Models

• Knockout mice for each dopamine receptor subtype
• Transgenic models with human SNCA mutations
• 6-OHDA lesioned rats for PD research

Background

The dopamine receptor family has been studied extensively since the initial characterization of D1 and D2 receptors in the 1970s. Research has revealed the complexity of dopaminergic signaling and its role in both normal brain function and disease states.

Historical milestones include the development of selective D1 and D2 agonists and antagonists, the discovery of D3-D5 receptors, and the identification of receptor polymorphisms associated with neurological and psychiatric disorders.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Pathway Diagram

The following diagram shows the key molecular relationships involving Dopamine Receptor Neurons discovered through SciDEX knowledge graph analysis: